CSTL.US Castle Biosciences Inc

Healthcare Biotechnology USA Stocks
33.79 USD
Close of Nov 14, 2026
17.72 44.28
Market cap
USD 1.04B
P/E
-
P/B
2.22x
ROE
-5.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CSTL.US undervalued?

Graham number

The Graham number of Castle Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Castle Biosciences Inc fundamental analysis

No fundamental analysis for Castle Biosciences Inc yet.

Castle Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Castle Biosciences Inc

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification…

Full company profile